Therefore, we feel that TGM2 with its potential role as a modifier of the ECM texture represents an extremely interesting biomarker, but that the clinical validation should probably address earlier pre-neoplastic lesions rather than DCIS. This evidence concerns the gene TGM2 and ductal breast carcinoma in situ.